Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Xu

Showing results (261-270 of 357) with videos related to

Pageof 36
Sort By:
Cell|March 29, 2024
Flexible scaffold-based cheminformatics approach for polypharmacological drug designZhangcheng Chen, Jing Yu, Huan Wang, et al.
Carcinogenesis|April 25, 2015
A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variantsFeng Sun, Inthrani R Indran, Zhi Wei Zhang, et al.
Nature Chemical Biology|September 24, 2021
Ligand recognition and G-protein coupling selectivity of cholecystokinin A receptorQiufeng Liu, Dehua Yang, Youwen Zhuang, et al.
Molecular Cell|June 17, 2022
GPCRs steer G<sub>i</sub> and G<sub>s</sub> selectivity via TM5-TM6 switches as revealed by structures of serotonin receptorsSijie Huang, Peiyu Xu, Dan-Dan Shen, et al.
Cell Metabolism|June 7, 2011
FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathwayMatthew J Potthoff, Jamie Boney-Montoya, Mihwa Choi, et al.
Nature Communications|April 28, 2022
A distinctive ligand recognition mechanism by the human vasoactive intestinal polypeptide receptor 2Yingna Xu, Wenbo Feng, Qingtong Zhou, et al.
The Journal of Biological Chemistry|June 16, 2017
Deconvoluting AMP-activated protein kinase (AMPK) adenine nucleotide binding and sensingXin Gu, Yan Yan, Scott J Novick, et al.
Cancer Letters|November 9, 2021
Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastasesShang Su, Jingchen Cao, Xiangqi Meng, et al.
Molecular Cell|February 1, 2020
Toward a Structural Understanding of Class B GPCR Peptide Binding and ActivationYi-Lynn Liang, Matthew J Belousoff, Peishen Zhao, et al.
Endocrinology|December 6, 2003
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gammaMaura Agostini, Mark Gurnell, David B Savage, et al.
Pageof 36

Showing results (261-270 of 357) with videos related to

Sort By:
Pageof 36
Cell|March 29, 2024
Flexible scaffold-based cheminformatics approach for polypharmacological drug designZhangcheng Chen, Jing Yu, Huan Wang, et al.
Carcinogenesis|April 25, 2015
A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variantsFeng Sun, Inthrani R Indran, Zhi Wei Zhang, et al.
Nature Chemical Biology|September 24, 2021
Ligand recognition and G-protein coupling selectivity of cholecystokinin A receptorQiufeng Liu, Dehua Yang, Youwen Zhuang, et al.
Molecular Cell|June 17, 2022
GPCRs steer G<sub>i</sub> and G<sub>s</sub> selectivity via TM5-TM6 switches as revealed by structures of serotonin receptorsSijie Huang, Peiyu Xu, Dan-Dan Shen, et al.
Cell Metabolism|June 7, 2011
FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathwayMatthew J Potthoff, Jamie Boney-Montoya, Mihwa Choi, et al.
Nature Communications|April 28, 2022
A distinctive ligand recognition mechanism by the human vasoactive intestinal polypeptide receptor 2Yingna Xu, Wenbo Feng, Qingtong Zhou, et al.
The Journal of Biological Chemistry|June 16, 2017
Deconvoluting AMP-activated protein kinase (AMPK) adenine nucleotide binding and sensingXin Gu, Yan Yan, Scott J Novick, et al.
Cancer Letters|November 9, 2021
Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastasesShang Su, Jingchen Cao, Xiangqi Meng, et al.
Molecular Cell|February 1, 2020
Toward a Structural Understanding of Class B GPCR Peptide Binding and ActivationYi-Lynn Liang, Matthew J Belousoff, Peishen Zhao, et al.
Endocrinology|December 6, 2003
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gammaMaura Agostini, Mark Gurnell, David B Savage, et al.
Pageof 36